JAMA Cardiology

Among adults in Kenya, an -enhanced demonstrated high sensitivity and negative predictive value for detecting left ventricular systolic dysfunction, supporting scalable screening in resource-limited settings.

https://ja.ma/4adjUBE

In patients with obstructive , aficamten improved exercise measures, including peak oxygen uptake and recovery, compared to metoprolol, supporting its use as first-line therapy for symptomatic oHCM.

https://ja.ma/3SzLFya

💬 Editor's Note by JAMA Cardiology Associate Editor Gregg C. Fonarow, MD, and Deputy Editor John J. V. McMurray, MD: A post hoc analysis of a multinational trial compared with in patients with , extending evaluation beyond the traditional cardiovascular composite endpoint to include broader cardiorenal outcomes.

Tirzepatide was associated with a statistically significant reduction in this expanded composite. However, the exploratory design and use of a comparator dose selected at trial initiation limit conclusions, and the analysis highlights the need for dedicated outcome studies to clarify incremental benefits of dual incretin therapies.

https://ja.ma/3QMROGR